Product Details for NDA 200678
KOMBIGLYZE XR (METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE)
500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Marketing Status: Discontinued
1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Marketing Status: Discontinued
1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Marketing Status: Discontinued
500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Marketing Status: Discontinued
Active Ingredient: METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Proprietary Name: KOMBIGLYZE XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N200678
Product Number: 001
Approval Date: Nov 5, 2010
Applicant Holder Full Name: ASTRAZENECA AB
Marketing Status: Discontinued
Patent and Exclusivity Information
KOMBIGLYZE XR (METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE)
Proprietary Name: KOMBIGLYZE XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N200678
Product Number: 001
Approval Date: Nov 5, 2010
Applicant Holder Full Name: ASTRAZENECA AB
Marketing Status: Discontinued
Patent and Exclusivity Information
1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Marketing Status: Discontinued
Active Ingredient: METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Proprietary Name: KOMBIGLYZE XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N200678
Product Number: 003
Approval Date: Nov 5, 2010
Applicant Holder Full Name: ASTRAZENECA AB
Marketing Status: Discontinued
Patent and Exclusivity Information
KOMBIGLYZE XR (METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE)
Proprietary Name: KOMBIGLYZE XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N200678
Product Number: 003
Approval Date: Nov 5, 2010
Applicant Holder Full Name: ASTRAZENECA AB
Marketing Status: Discontinued
Patent and Exclusivity Information
1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Marketing Status: Discontinued
Active Ingredient: METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Proprietary Name: KOMBIGLYZE XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N200678
Product Number: 002
Approval Date: Nov 5, 2010
Applicant Holder Full Name: ASTRAZENECA AB
Marketing Status: Discontinued
Patent and Exclusivity Information
Proprietary Name: KOMBIGLYZE XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N200678
Product Number: 002
Approval Date: Nov 5, 2010
Applicant Holder Full Name: ASTRAZENECA AB
Marketing Status: Discontinued
Patent and Exclusivity Information